JP7250519B2 - Ｐｄ－１及び４－１ｂｂの融合タンパク質 - Google Patents

Ｐｄ－１及び４－１ｂｂの融合タンパク質 Download PDF

Info

Publication number
JP7250519B2
JP7250519B2 JP2018549452A JP2018549452A JP7250519B2 JP 7250519 B2 JP7250519 B2 JP 7250519B2 JP 2018549452 A JP2018549452 A JP 2018549452A JP 2018549452 A JP2018549452 A JP 2018549452A JP 7250519 B2 JP7250519 B2 JP 7250519B2
Authority
JP
Japan
Prior art keywords
cells
fusion protein
nucleic acid
amino acid
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018549452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512251A5 (https=
JP2019512251A (ja
Inventor
ノエスナー，エルフリーデ
シュレンカー，ラモナ
ヴァイツ，シュテファン
Original Assignee
ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー） filed Critical ヘルムホルツ ツェントゥルム ミュンヘン ドイチェス フォルシュングスツェントゥルム フューア ゲズントハイト ウント ウムヴェルト （ゲーエムベーハー）
Publication of JP2019512251A publication Critical patent/JP2019512251A/ja
Publication of JP2019512251A5 publication Critical patent/JP2019512251A5/ja
Priority to JP2023045262A priority Critical patent/JP7746323B2/ja
Application granted granted Critical
Publication of JP7250519B2 publication Critical patent/JP7250519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018549452A 2016-03-23 2017-03-23 Ｐｄ－１及び４－１ｂｂの融合タンパク質 Active JP7250519B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023045262A JP7746323B2 (ja) 2016-03-23 2023-03-22 Ｐｄ－１及び４－１ｂｂの融合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LULU93006 2016-03-23
LU93006 2016-03-23
PCT/EP2017/056931 WO2017162797A1 (en) 2016-03-23 2017-03-23 Fusion proteins of pd-1 and 4-1bb

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023045262A Division JP7746323B2 (ja) 2016-03-23 2023-03-22 Ｐｄ－１及び４－１ｂｂの融合タンパク質

Publications (3)

Publication Number Publication Date
JP2019512251A JP2019512251A (ja) 2019-05-16
JP2019512251A5 JP2019512251A5 (https=) 2019-09-19
JP7250519B2 true JP7250519B2 (ja) 2023-04-03

Family

ID=55702054

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018549452A Active JP7250519B2 (ja) 2016-03-23 2017-03-23 Ｐｄ－１及び４－１ｂｂの融合タンパク質
JP2023045262A Active JP7746323B2 (ja) 2016-03-23 2023-03-22 Ｐｄ－１及び４－１ｂｂの融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023045262A Active JP7746323B2 (ja) 2016-03-23 2023-03-22 Ｐｄ－１及び４－１ｂｂの融合タンパク質

Country Status (8)

Country Link
US (3) US11365237B2 (https=)
EP (2) EP3433269B1 (https=)
JP (2) JP7250519B2 (https=)
CN (1) CN109195985B (https=)
AU (1) AU2017236069B2 (https=)
CA (1) CA3017036A1 (https=)
ES (1) ES2962588T3 (https=)
WO (1) WO2017162797A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3298033T5 (pl) 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
DK3909972T5 (da) 2015-06-19 2024-08-05 Sebastian Kobold Pd1-cd28-fusionsproteiner og disses anvendelse i medicin
EP3433269B1 (en) * 2016-03-23 2023-09-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
JP7291396B2 (ja) 2016-11-22 2023-06-15 ティーシーアール２ セラピューティクス インク． 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
AU2017382243A1 (en) * 2016-12-22 2019-05-02 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
WO2018181390A1 (ja) * 2017-03-31 2018-10-04 東亞合成株式会社 Ｐｄ－１シグナル配列を有する抗腫瘍ペプチドおよびその利用
EP3820887A4 (en) * 2018-07-11 2022-04-20 KAHR Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
KR102351041B1 (ko) * 2018-12-19 2022-01-13 한국화학연구원 인간 lrrc24 단백질 유래 세포막 투과 도메인
EP3908664A4 (en) * 2019-01-07 2023-01-25 Thomas Jefferson University MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES
AU2020315796A1 (en) * 2019-07-19 2022-02-24 Memorial Hospital For Cancer And Allied Diseases Fusion polypeptide for immunotherapy
CN115956086A (zh) * 2020-05-06 2023-04-11 萨摩亚商柏沛生医股份有限公司 用于针对癌症及传染病的免疫疗法的融合蛋白
WO2022036495A1 (en) * 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CA3198363A1 (en) * 2020-10-09 2022-04-14 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions comprising pd1 chimeric polypeptides
KR102618718B1 (ko) * 2021-01-11 2023-12-29 주식회사 유틸렉스 항-4-1bb 항체 및 pd-1 단백질 또는 이의 단편을 포함하는 이중특이적 에피토프 결합 단백질 및 이의 용도
WO2023025779A1 (en) * 2021-08-25 2023-03-02 Medigene Immunotherapies Gmbh Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors
US20260055159A1 (en) * 2022-08-23 2026-02-26 Medigene Immunotherapies Gmbh Combination of ny-eso-1 specific t cell receptors and chimeric co-stimulatory receptors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014001222A (es) * 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
US9688740B2 (en) * 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
JP6493692B2 (ja) * 2013-03-15 2019-04-10 セルジーン コーポレイション 修飾されたｔリンパ球
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CN105377897A (zh) 2013-05-03 2016-03-02 俄亥俄州创新基金会 Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
ES2878449T3 (es) * 2014-07-24 2021-11-18 2Seventy Bio Inc Receptores antigénicos quiméricos de BCMA
EP4205749A1 (en) * 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
BR112017013981A2 (pt) * 2015-01-26 2018-01-02 Cellectis receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer
US10828353B2 (en) * 2015-01-31 2020-11-10 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
WO2016138846A1 (en) * 2015-03-02 2016-09-09 Shanghai Sidansai Biotechnology Co., Ltd Reducing immune tolerance induced by pd‐l1
EP4406604A3 (en) * 2015-03-05 2024-10-23 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
PL3298033T5 (pl) * 2015-05-18 2023-10-30 TCR2 Therapeutics Inc. Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
DK3909972T5 (da) * 2015-06-19 2024-08-05 Sebastian Kobold Pd1-cd28-fusionsproteiner og disses anvendelse i medicin
JP2018520679A (ja) * 2015-06-29 2018-08-02 ザ・ジョンズ・ホプキンス・ユニバーシティー 免疫チェックポイントキメラ抗原受容体療法
CA2997551A1 (en) * 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
JP2019509738A (ja) * 2016-03-11 2019-04-11 ブルーバード バイオ， インコーポレイテッド ゲノム編集された免疫エフェクター細胞
EP3433269B1 (en) * 2016-03-23 2023-09-27 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
CN111819192A (zh) * 2018-03-02 2020-10-23 艾洛基治疗公司 可诱导的嵌合细胞激素受体
EP3774906A1 (en) * 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Am. J. Transl. Res.，2015年，Vol. 7，p. 460-473
JNCI Natl. Cancer Inst.，2015年，Vol. 107, djv146，p. 1-10
SCHLENKER, Ramona，Chimeric co-stimulatory receptors as a strategy to improve the performance of T cells in the tumor environment，Dissertation，p. 1-132，2015年

Also Published As

Publication number Publication date
EP3433269A1 (en) 2019-01-30
EP3433269B1 (en) 2023-09-27
CA3017036A1 (en) 2017-09-28
US12516101B2 (en) 2026-01-06
US20240247046A1 (en) 2024-07-25
ES2962588T3 (es) 2024-03-20
WO2017162797A1 (en) 2017-09-28
EP3433269C0 (en) 2023-09-27
AU2017236069B2 (en) 2021-04-08
JP7746323B2 (ja) 2025-09-30
US20190106478A1 (en) 2019-04-11
JP2023078362A (ja) 2023-06-06
EP4286522A3 (en) 2024-02-28
US20220380435A1 (en) 2022-12-01
CN109195985B (zh) 2022-07-26
JP2019512251A (ja) 2019-05-16
CN109195985A (zh) 2019-01-11
NZ745944A (en) 2025-05-30
AU2017236069A1 (en) 2018-09-20
EP4286522A2 (en) 2023-12-06
US11365237B2 (en) 2022-06-21

Similar Documents

Publication Publication Date Title
JP7746323B2 (ja) Ｐｄ－１及び４－１ｂｂの融合タンパク質
JP7460675B2 (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
ES2963718T3 (es) Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
CN111836827B (zh) 包含nkg2d结构域的多特异性嵌合受体和其使用方法
KR20170120701A (ko) 면역조절 융합 단백질 및 그 용도
CN110494558B (zh) Gamma delta t细胞和增强其杀肿瘤活性的方法
CN108137670A (zh) Ny-eso-1特异性tcr及其使用方法
WO2022060806A1 (en) Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
JP2024541976A (ja) キメラアダプターポリペプチド
WO2023077100A1 (en) T cell receptor recognizing r175h mutation in p53 and its application
KR20260033032A (ko) 합성 시토카인 수용체
HK40109405A (en) Pd1-cd28 fusion proteins and their use in medicine
HK40064520B (en) Pd1-cd28 fusion proteins and their use in medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190807

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230322

R150 Certificate of patent or registration of utility model

Ref document number: 7250519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250